MedTrace Logo

Supporting Medtronic 780G Insulin Pump Adoption in Latino Patients: A Spanish - Language Training Initiative

NCT07720388 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-08-11

No results posted yet for this study

Summary

This study plans to learn more about whether a support program delivered in Spanish or both English and Spanish for bilingual families helps Latino youth with Type 1 Diabetes (T1D) successfully use the Medtronic MiniMed 780G system.

The main question it aims to answer is:

Does a linguistically and culturally tailored onboarding model for an automated insulin delivery system close the gap in technology adoption and improve health outcomes?

Participants will:

* Use the Medtronic MiniMed 780G Automated Insulin Delivery system for eight months
* Attend one in-person nutrition support and insulin pump start class
* Participate in regular virtual check-ins with native Spanish-speaking study team members

Conditions

  • Diabetes Mellitus, Type 1 Diabetes

Interventions

OTHER

Culturally and linguistically tailored onboarding and support program

The intervention is a structured, eight-month, culturally and linguistically tailored onboarding and support program for the Medtronic MiniMed 780G system. This includes: * Utilization of the Medtronic MiniMed 780G Automated Insulin Delivery system * One-on-one nutrition support with a Registered Dietitian * A pump start class conducted in Spanish or both English and Spanish for bilingual participants by a Certified Diabetes Educator * Virtual check-ins between the participant and study coordinator

DEVICE

Medtronic MiniMed 780G Insulin Pump System

Participants will receive a Medtronic MiniMed 780G Automated Insulin Delivery system, an FDA-approved advanced hybrid closed-loop insulin delivery system that integrates with continuous glucose monitoring technology. A unique feature of the device is its availability with a Spanish-language menu and user interface, which may improve accessibility for Spanish-speaking users and families. Participants will complete standard pump onboarding and training and will use the system as part of their routine diabetes management for up to 8 months.

Sponsors & Collaborators

  • Barbara Davis Center of Childhood Diabetes, University of Co

    collaborator UNKNOWN

  • University of Colorado, Denver

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Max Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2027-01-31
Completion
2027-03-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07720388 on ClinicalTrials.gov